Merck's CAPVAXIVE™ ($MRK) Vaccine Shows Positive Results in At-Risk Adults

Oct 16, 2024, 10:51 AM

Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) has demonstrated positive immune responses in adults with an increased risk for pneumococcal disease. The new Phase 3 data was shared at IDWeek 2024, highlighting the vaccine's efficacy in providing immune protection against pneumococcal disease, a significant concern for at-risk populations. The vaccine's development is a notable achievement for Merck ($MRK).